Showcasing Novel Linker & Conjugation Technologies to Optimize Stability, Unlock New Payloads, & Reduce Off-Target Toxicity to Better Balance Safety & Efficacy
ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution is placing unprecedented pressure on linker architecture and conjugation chemistry to control stability, reduce off-target toxicity, overcome tumor resistance, and maintain manufacturability.
To meet these challenges head on, the 4th ADC Linker & Conjugation Summit offers a highly technical, deeply curated environment built specifically for specialists working at the cutting edge of ADC chemistry. At this summit, you aren’t lost in a crowd, you’re surrounded by peers who share the same job titles, scientific focus, and day-to-day challenges. Every session is built for specialists, every conversation is relevant, and every detail is designed to advance real chemistry solutions.
Over three focused days, 80+ ADC chemists, protein engineers, and translational scientists will dissect the core chemistry questions shaping next generation ADC performance. With 20+ expert-led case studies from leading biopharma and biotech innovators, you’ll gain actionable insights to engineer homogeneous ADCs, prevent premature payload release, enable orthogonal dual payload systems, mitigate hydrophobicity driven aggregation, and integrate predictive modeling into platform design.
Through hands-on workshops, technical debates, and collaborative networking, this summit gives you the rare opportunity to shape the linker and conjugation strategies that will define the next decade of ADC development.
The timing and content of the talks was fantastic.
2025 Attendee, Johnson & Johnson
I enjoyed that it was a very specific crowd of experts in (as the name indicates) Linker & Conjugation - especially that it wasn't only big pharma based but a nice mixtures of pharmaceutical companies, biotech, start-up and even academia-based professors. I appreciated that it wasn't too big of a crowd either, so you had the chance to meet and connect with everyone (kudos for the speed networking as well). I think having the first pre-conference workshop day was really good also, this featured some interesting conversations and set the tone for the rest of the conference. Choice of speakers/topics was really well done as well, learnt some new things from the fields!
2025 Speaker, ADC Therapeutics
What’s New?
Explore the Full Event Guide
The 4th ADC Linker & Conjugation Summit is the only dedicated platform focused solely on solving the chemistry challenges underpinning next-generation ADC design.
Highlights Include:
- 20+ expert speakers from leading big pharma and biotech organizations advancing linker and conjugation innovation
- Actionable, technical insights into site-specific, enzymatic, glycan-directed, click-chemistry, and pyridazinedione-based conjugation strategies
- Case studies on dual-payload ADCs, high-DAR constructs, degrader-antibody conjugates, and orthogonal conjugation platforms
- 2 interactive pre-conference workshops bridging chemistry with PK/PD and translational performance
2025 Speaker Faculty Included:
Official Partners
Attending Companies Include
Explore the Agenda
Gain actionable insights from expert-led sessions on advanced linker design, next-generation bioconjugation chemistries, and strategies to minimize off-target toxicity.
Partner With Us
Connect with 80+ ADC linker and conjugation leaders actively seeking solutions to advance the design, production and testing their of next-generation ADC technologies.
Join ADC Linker & Conjugation Experts
Network with senior scientists and highly technical experts working at the cutting edge of ADC chemistry, alongside key decision makers from leading biopharma organizations, in dedicated sessions designed to build meaningful collaborations.